The infection risks of JAK inhibition

References

• Choy EH. Clinical significance of janus kinase inhibitor selectivity. Rheumatology. 2019;58(6):953–962.
   PubMed Web of Science ®Google Scholar
• Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. Epub 2007/ 02/22. PubMed PMID: 17312100 2007;178(5):2623–2629.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24. Epub 2002/ 06/01. PubMed PMID: 12039028
   PubMed Web of Science ®Google Scholar
• Satarker S, Tom AA, Shaji RA, et al.jak-stat pathway inhibition and their implications in COVID-19 therapy.Postgrad Med.2021;133(5):489–507; Epub 2020/ 12/16. PubMed PMID: 33245005
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of JAK–STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
   PubMed Web of Science ®Google Scholar
• Majri SS, Fritz JM, Villarino AV, et al. STAT5B: a differential regulator of the life and death of cd4+ effector memory t cells. J Immunol. 2018;200(1):110–118.
   PubMed Web of Science ®Google Scholar
• Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104(3):499–514.
   PubMed Web of Science ®Google Scholar
• Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33(3):388–391.
   PubMed Web of Science ®Google Scholar
• Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome. J Allergy Clin Immunol. 2013;131(6):1611–1623. e3.
   PubMed Web of Science ®Google Scholar
• You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334–351.
   PubMed Web of Science ®Google Scholar
• Nice.org.Uk. 2021. 1 recommendations | filgotinib for treating moderate to severe rheumatoid arthritis | guidance | NICE. [ online] [cited 2021 Nov 16]. Available at: <https://www.nice.org.uk/guidance/ta676/chapter/1-Recommendations>
   Google Scholar
• European Medicines Agency. 2021. Jyseleca - European medicines agency. [ online] [cited 2021 Nov 16]. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca>
   Google Scholar
• Listing J, Gerhold K, Zink A.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.Rheumatology (Oxford).2013;52(1):53–61; Epub 2012/ 11/30. PubMed PMID: 23192911;
   PubMed Web of Science ®Google Scholar
• Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease‐modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2008;59(8):1074–1081.
   Web of Science ®Google Scholar
• Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–1262. Epub 2017/ 02/02. PubMed PMID: 28143815; PubMed Central PMCID: PMCPMC5530353
   PubMed Web of Science ®Google Scholar
• Alves C, Penedones A, Mendes D, et al.The risk of infections associated with jak inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis.J Clin Rheumatol.2021; Epub 2021/ 04/27. doi https://doi.org/10.1097/rhu.0000000000001749. PubMed PMID: 33902098;
   Google Scholar
• Bertoldi I, Caporali R. Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis. Open Access Rheumatol. 2021;13:221–237. PubMed PMID: 34349573.
   PubMed Web of Science ®Google Scholar
• Smolen J, Genovese M, Takeuchi T, et al. THU0166 safety profile of baricitinib in patients with active ra: an integrated analysis. Ann Rheum Dis. 2016;75(Suppl 2):243–244.
   Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. Epub 2015/ 12/17. PubMed PMID: 26669566; PubMed Central PMCID: PMCPMC4704538
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the british society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology. 2010;50(1):124–131.
   PubMed Web of Science ®Google Scholar
• Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–1419. Epub 2020/ 06/06. PubMed PMID: 32499126
   PubMed Web of Science ®Google Scholar
• Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020;31(Suppl1): 129–136. PubMed PMID: PMC7361184
   PubMedGoogle Scholar
• MAdÁ M, CSd M, Guerra SF, et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018;20(1):60.
   PubMedGoogle Scholar
• Pawar A, Desai RJ, Gautam N, et al. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020;2(2):e84–e98.
   Google Scholar
• Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1290–1297. Epub 2020/ 08/14. PubMed PMID: 32788396
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Nakano K, Nakayamada S, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021;80(9):1130–1136. Epub 2021/ 04/09. PubMed PMID: 33827788; PubMed Central PMCID: PMCPMC8372380
   PubMed Web of Science ®Google Scholar
• Clarke B, Yates M, Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Supplement_2):24–30.
   Google Scholar
• Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg J-E, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–325.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–2311.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009–1019.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998–1008.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kremer JM, Van Den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. Epub 2018/ 06/18. PubMed PMID: 29908669
   PubMed Web of Science ®Google Scholar
• Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. Epub 2019/ 12/04. PubMed PMID: 31791386; PubMed Central PMCID: PMCPMC6889334
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (select-early): a multicenter, multi-country, randomized, double-blind, active comparator–controlled trial. Arthritis Rheumatol. 2020;72(10):1607–1620.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–1800. Epub 2019/ 07/10. PubMed PMID: 31287230
   PubMed Web of Science ®Google Scholar
• Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779–787.
   PubMed Web of Science ®Google Scholar
• Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23(1):9. PubMed PMID: 33407801.
   PubMedGoogle Scholar
• Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase ii rheumatoid arthritis programs. J Rheumatol. 2021;48(8):1230–1238.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Winthrop K, Tanaka Y, et al. Thu0202 integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials. Ann Rheum Dis. 2020;79(1):324–325.
   PubMedGoogle Scholar
• European Medicines Agency EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots, 2020. [cited 2021 Nov 16]. Available: https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf.
   Google Scholar
• Klünder B, Mohamed MF, Othman AA.Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase i and ii clinical trials.Clin Pharmacokinet.2018;57(8):977–988; Epub 2017/ 10/28. PubMed PMID: 29076110.;
   PubMed Web of Science ®Google Scholar
• Ema.Europa.Eu. European Medicines Agency. 2021. [cited 2021 Nov 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
   Google Scholar
• Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328–2337. Epub 2016/ 03/19. PubMed PMID: 26990731; PubMed Central PMCID: PMCPMC5396838.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):e347–e57.
   Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395.
   PubMed Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):1755–1766.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Sato S, Kurushima S, et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):197.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol (Hoboken). 2014;66(10):2675–2684. Epub 2014/ 06/20. PubMed PMID: 24943354; PubMed Central PMCID: PMCPmc4285807
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80(3):304–311. Epub 2020/ 10/30. PubMed PMID: 33115760; PubMed Central PMCID: PMCPMC7892382
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848–858.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133–1138. Epub 2015/ 09/01. PubMed PMID: 26318385; PubMed Central PMCID: PMCPMC4893093
   PubMed Web of Science ®Google Scholar
• Balish E, Wagner RD, Vázquez-Torres A, et al.Candidiasis in interferon-gamma knockout (IFN-gamma-/-) mice.J Infect Dis.1998;178(2):478–487; Epub 1998/ 08/11. PubMed PMID: 9697730;
   PubMed Web of Science ®Google Scholar
• Chen Y, Gong FY, Li ZJ, et al. A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Sci Rep. 2017;7(1):6779. Epub 2017/ 07/30. PubMed PMID: 28754958; PubMed Central PMCID: PMCPMC5533717
   PubMedGoogle Scholar
• Weber ANR, Bittner Z, Liu X, et al. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454. Epub 2017/ 11/24. PubMed PMID: 29167667; PubMed Central PMCID: PMCPMC5682317
   PubMed Web of Science ®Google Scholar
• Boots AM, Maier AB, Stinissen P, et al.The influence of ageing on the development and management of rheumatoid arthritis.Nat Rev Rheumatol.2013;9(10):604–613; Epub 2013/ 06/19. PubMed PMID: 23774902
   PubMed Web of Science ®Google Scholar
• Chalan P, van Den Berg A, Kroesen BJ, et al.Rheumatoid arthritis, immunosenescence and the hallmarks of aging.Curr Aging Sci.2015;8(2):131–146; Epub 2015/ 07/28. PubMed PMID: 26212057; PubMed Central PMCID: PMCPMC5388800
   PubMedGoogle Scholar
• Winthrop KL, Citera G, Gold D, et al. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis. 2021;80(1):134–136. Epub 2020/ 10/12. PubMed PMID: 33046447
   PubMed Web of Science ®Google Scholar
• Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(11):2924–2937. Epub 2014/ 07/23. PubMed PMID: 25047021
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015. Epub 2015/ 11/08. PubMed PMID: 26545825;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687–695. Epub 2015/ 03/22. PubMed PMID: 25795907; PubMed Central PMCID: PMCPMC4819610
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
   PubMed Web of Science ®Google Scholar
• Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. Epub 2020/ 11/08. PubMed PMID: 33158881; PubMed Central PMCID: PMCPMC7788060
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase ii trial. Arthritis Rheumatol. 2017;69(10):1969–1977. Epub 2017/ 08/29. PubMed PMID: 28845577; PubMed Central PMCID: PMCPMC5656925
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase iiib/iv randomized study. Arthritis Care Res (Hoboken). 2020;72(3):353–359. Epub 2019/06/18. PubMed PMID: 31207152; PubMed Central PMCID: PMCPMC7064887
   PubMed Web of Science ®Google Scholar
• Cheetham TC, Marcy SM, Tseng HF, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–873. Epub 2015/06/09. PubMed PMID: 26051268
   PubMed Web of Science ®Google Scholar
• Bubb MR.Risk of disseminated varicella zoster in immunosuppressed patients receiving zoster vaccination.Mayo Clin Proc.2015;90(11):1585–1586; Epub 2015/11/07. PubMed PMID: 26541254
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters A, Choy EH, et al. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Ann Rheum Dis. 2020;79(5):669–671. Epub 2020/03/13. PubMed PMID: 32161057; PubMed Central PMCID: PMCPMC7213307
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. Epub 2016/09/15. PubMed PMID: 27626517
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. Epub 2015/04/29. PubMed PMID: 25916341
   PubMed Web of Science ®Google Scholar
• Stevens E, Weinblatt ME, Massarotti E, et al.Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center’s experience with 400 patients.ACR Open Rheumatol.2020;2(6):357–361; Epub 2020/05/16. PubMed PMID: 32412669; PubMed Central PMCID: PMCPMC7301873
   PubMedGoogle Scholar
• Favalli EG, Bugatti S, Klersy C, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020;22(1):290. PubMed PMID: 33380344
   PubMed Web of Science ®Google Scholar
• Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–6416. PubMed PMID: 32809969
   PubMed Web of Science ®Google Scholar
• C-x C, J-j W, Li H, et al. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021;35(9):2616–2620.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807. Epub 2020/12/12. PubMed PMID: 33306283; PubMed Central PMCID: PMCPMC7745180
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407–1418. Epub 2021/09/05. PubMed PMID: 34480861
   PubMed Web of Science ®Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406–415. PubMed PMID: 34133856
   PubMed Web of Science ®Google Scholar
• “Therapeutic Management Of Hospitalized Adults With COVID-19”. nih.gov. The National Institute of Health. 2021. [cited 2021 Nov 16]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults–therapeutic-management/.
   Google Scholar
• “Baricitinib To Be Investigated As A Possible Treatment For COVID-19 In The RECOVERY Trial — RECOVERY Trial. Randomised Evaluation of COVID-19 Therapy.”. Recoverytrial.Net, 2021. [cited 2021 Nov 16]. Available from: https://www.recoverytrial.net/news/baricitinib-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial.
   Google Scholar